Supreme Court temporarily extends women’s access to a widely used abortion pill - Scorecard - MDSpire

Supreme Court temporarily extends women’s access to a widely used abortion pill

  • By

  • Associated Press

  • May 11, 2026

  • 0 min

Share

Clinical Scorecard: Supreme Court Temporarily Preserves Access to Commonly Used Abortion Medication

At a Glance

CategoryDetail
ConditionAccess to mifepristone for abortion
Key MechanismsMifepristone is used in combination with misoprostol for medication abortions.
Target PopulationWomen seeking abortions
Care SettingPharmacies and telehealth services

Key Highlights

  • Supreme Court allows continued access to mifepristone pending further review.
  • Medication abortions accounted for nearly two-thirds of all abortions in the U.S. in 2023.
  • FDA has repeatedly deemed mifepristone safe and effective since its approval in 2000.
  • Mainstream medical groups and pharmaceutical industry caution against limiting access.
  • Ongoing legal challenges question the safety and prescribing rules of mifepristone.

Guideline-Based Recommendations

Diagnosis

  • Assess eligibility for medication abortion based on FDA guidelines.

Management

  • Continue prescribing mifepristone and misoprostol as per FDA recommendations.

Monitoring & Follow-up

  • Monitor for any adverse effects and report complications as required.

Risks

  • Legal challenges may impact access and prescribing practices.

Patient & Prescribing Data

Women seeking medication abortions.

Mifepristone is often prescribed without in-person doctor visits.

Clinical Best Practices

  • Follow FDA guidelines for prescribing mifepristone.
  • Ensure patients are informed about the medication and its use.

Related Resources & Content

Original Source(s)

Supreme Court temporarily extends women’s access to a widely used abortion pill

  • by Associated Press

  • May 11, 2026

Related Content

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

Rethinking Menopause Hormone Therapy

A JAMA Perspective outlines how updated FDA labeling may reshape menopause care.